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Abstract
Lung cancer is the leading cause of cancer death; 80–85% of lung cancer cases are non-small cell lung cancer (NSCLC).
Smoking is a documented risk factor for the development of this cancer. Although nicotine does not have the ability to
initiate carcinogenic events, recent studies have implicated nicotine in growth stimulation of NSCLC. Using three NSCLC cell
lines (NCI-H322, NCI-H441 and NCI-H1299), we identified the cooperation of nicotinic acetylcholine receptors (nAChRs) and
b-adrenergic receptors (b-ARs) as principal regulators of these effects. Proliferation was measured by thymidine
incorporation and MTT assays, and Western blots were used to monitor the upregulation of the nAChRs and activation of
signaling molecules. Noradrenaline and GABA were measured by immunoassays. Nicotine-treated NSCLC cells showed
significant induction of the a7nAChR and a4nAChR, along with significant inductions of p-CREB and p-ERK1/2 accompanied
by increases in the stress neurotransmitter noradrenaline, which in turn led to the observed increase in DNA synthesis and
cell proliferation. Effects on cell proliferation and signaling proteins were reversed by the a7nAChR antagonist a-BTX or the
b-blocker propranolol. Nicotine treatment also down-regulated expression of the GABA synthesizing enzyme GAD 65 and
the level of endogenous GABA, while treatment of NSCLC cells with GABA inhibited cell proliferation. Interestingly, GABA
acts by reducing b-adrenergic activated cAMP signaling. Our findings suggest that nicotine-induced activation of this
autocrine noradrenaline-initiated signaling cascade and concomitant deficiency in inhibitory GABA, similar to modulation of
these neurotransmitters in the nicotine-addicted brain, may contribute to the development of NSCLC in smokers. Our data
suggest that exposure to nicotine either by tobacco smoke or nicotine supplements facilitates growth and progression of
NSCLC and that pharmacological intervention by b blocker may lower the risk for NSCLC development among smokers and
could be used to enhance the clinical outcome of standard cancer therapy.
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Introduction
Lung cancer is the leading cause of cancer-related mortality in
both men and women in the United States, with a similar trend
documented globally. Industrialized regions such as North
America and Europe have the highest rates [1]. The family of
non-small cell lung cancers (NSCLC) consists of adenocarcinoma,
squamous cell carcinoma and large cell carcinoma. NSCLC is
highly resistant to existing cancer therapeutics, and the survival
rate beyond 2 years is still discouraging despite recent advances in
the development of novel agents that target epidermal growth
factor or angiogenesis factors [2]. NSCLC accounts for about 80%
of all lung cancer cases, with adenocarcinoma predominating.
Smoking is a documented risk factor for NSCLC and is primarily
responsible for the development of this cancer type in populations
exposed to smoking [3,4]. The nitrosated nicotine-derived
carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)
causes NSCLC in laboratory rodents [5,6] and has been identified
as a high affinity agonist for nicotinic acetylcholine receptors
(nAChRs) [7,8]. Cellular signaling in response to binding of NNK
to nAChRs has been implicated in the growth regulation of
NSCLC [9]. However, because the tobacco constituent nicotine is
less carcinogenic compared to its potent carcinogenic derivative
NNK, nicotine has attracted less interest for its role in smoking’s
effects on cancer growth and stimulation. It has been earlier shown
that nicotine stimulates angiogenesis via binding to a7 nAChR
[10], a process that may stimulate tumor growth. However, these
studies have addressed direct cellular responses to single doses of
nicotine or NNK, which may be termed acute exposures. Such a
protocol does not mimic real-life exposure where exposure to both
agents in smokers is chronic, suggesting that similar to the effects of
chronic nicotine in the brain, indirect mechanisms via the
nAChR-mediated production of neurotransmitters may be
involved. Moreover, nicotine replacement therapy may have
adverse effects on the clinical outcome of NSCLC therapy via such
mechanisms.
Nicotinic receptors are constituted of alpha subunits (homo-
meric nAChRs) or a combination of alpha and beta subunits
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to be restricted to the nervous system, and the receptors’ biology as
well as responses to acute and chronic nicotine have been
extensively studied in the brain [11]. However, more recent studies
have identified nAChRs in numerous non-neuronal mammalian
cells, where they regulate diverse cellular functions [12]. Research
examining the role of neuro-excitatory stimuli in the brain has
identified the homomeric a7nAChR as the regulator of excitatory
neurotransmitters, such as glutamate, and the stress neurotrans-
mitter noradrenaline, from which adrenaline is formed enzymat-
ically [13,14]; on the other hand, the heteromeric a4b2nAChR
regulates the inhibitory neurotransmitter c-aminobutyric acid
(GABA) [15]. Chronic exposure to nicotine upregulates the
protein expression of both receptors in the nervous system via
posttranscriptional mechanisms without an increase in gene
transcription [6,16,17]. The upregulation of a4b2nAChR protein
is the response to nicotine-induced, long-term desensitization that
reduces GABA production in the brain, an effect thought to cause
nicotine addiction and craving [11]. By contrast, protein
upregulation of the a7nAChR in the brain is not accompanied
by long-term receptor desensitization, resulting in enhanced
production of excitatory neurotransmitters [18].
It has been demonstrated that binding of nicotine to the
a7nAChR stimulated colon cancer cells indirectly by increasing
the production of noradrenaline, which in turn activated b-
adrenergic receptor (b-AR) signaling [19]. Noradrenaline is the
physiological agonist for the Gas-coupled b-ARs, and many of its
biological effects are caused by the activation of adenylyl cyclase
downstream of Gas that leads to the formation of intracellular
cAMP [20,21]. Noradrenaline has strong stimulating effects, via
beta-adrenergic receptor signaling, on a number of cancer types,
including cancer of the colon [19,22,23], prostate [24], ovary [25],
and pancreas [26]. It has also been shown that the selective b-
adrenergic agonist isoproterenol stimulates DNA synthesis of
human NSCLC cell lines [27]. A cooperative regulation seems to
be at work, as NNK is not only an agonist for nAChRs [7,8] but
also for b-ARs [28] and has been shown to stimulate proliferation
and migration of human NSCLC cell lines in vitro via signaling
effectors downstream of b-ARs. The beta-adrenergic signaling
cascade activated by NNK in these cells included the adenylyl
cyclase/cAMP/CREB pathway as well as PKA-dependent
transactivation of EGFR and its downstream effector, the
ERK1/2 cascade [28,29]. Such activation of cancer stimulatory
b-adrenergic signaling by NNK might also be the principal
regulatory mechanism involved in the action of its parent
compound, nicotine, because of its documented ability to cause
the release of noradrenaline and adrenaline.
In the current study, three human NSCLC cell lines (NCI-
H322, NCI-H441, NCI-H1299) were used to test the hypothesis
that acute or chronic nicotine-induced modulation of a7nAChR
and a4b2nAChR may contribute to the development and
progression of AC in smokers in a manner similar to changes in
these receptors in the nicotine-addicted brain, and that these
effects can be neutralized by c-amino butyric acid or a general
beta-blocker such as propranolol.
Materials and Methods
Cell lines and tissue culture
The human NSCLC cell line NCI-H322 (histological subtype:
adenocarcinoma with activating point mutation in K-ras) was
purchased from the European Collection of Cell Cultures (Health
Protection Agency, Porton Down, Salisbury, UK). The NSCLC
cell lines NCI-H441 (histological subtype: adenocarcinoma
without activating point mutation in K-ras) and NCI-H1299 cells
(non- small cell lung carcinoma which lacks p53 protein
expression, histological subtype not identified) were purchased
from American Type Culture Collection (Manassas, VA, USA);
Cell line NCI-H1299 was purchased by us 1 month earlier and
therefore did not require authentication by us. Cell lines NCI-
H322 and NCI-H441were purchased by us several years earlier
and were therefore authenticated by RADIL (Columbia, MO,
USA) by species-specific PCR. Cells were maintained in RPMI-
1640 culture medium (Gibco, Frederick, MD, USA) supplemented
with fetal bovine serum (10% v/v), free of antibiotics at 37uCi na n
atmosphere of 5% CO2 [29]. Similar to the majority of human
NSCLCs [30], NCI-H322 carries k-ras point mutation while NCI-
H441 does not have such a mutation.
ELISA immunoassays for the detection of noradrenaline
and GABA
Neurotransmitter production mediated by nAChRs in response
to a single dose of nicotine was determined by acute exposure of
cells for 30 minutes to 1 mM nicotine (nicotine [-]-tartrate, Sigma,
St. Louis, MO, USA) in the presence or absence of the selective
a7nAChR antagonist a-bungarotoxin (a-BTX, 200 nM, Calbio-
chem, Gibbstown, NJ, USA) or the selective a4b2nAChR
antagonist N-n-decylnicotinium iodide (NDNI 200 nM, Sigma).
Chronic exposure of cells with nicotine (1 mM) was conducted for
7 days in basal medium containing heat-inactivated horse serum
(Sigma) as the only additive with replacement of nicotine every
24 hours. Control cells were maintained under identical condi-
tions for 7 days without nicotine. In order to measure modulations
in the sensitivity of a7nAChR and a4b2nAChR to chronic
nicotine, control cells and nicotine pretreated cells were then
washed with PBS and exposed for 30 minutes in basal medium to
nicotine at concentrations from 10 nM through 10 mM, and
noradrenaline and GABA were analyzed by immunoassays. For
determination of EC50 values, the data were analyzed by nonlinear
regression and fitted to sigmoidal dose-response curves with
variable slopes, using Prism GraphPad software (San Diego, CA,
USA). For the nonlinear regression analysis of the ascending
curves for noradrenaline, as a restraint for the calculation the
EC50, the values for the untreated control cells were entered as
bottom of the curve (minimum). For the nonlinear regression
analysis of the descending GABA curves, as a restraint for the
calculation of the EC50, the values for the untreated control cells
were entered as top of the curve (maximum). The EC50 values
were tested for significant differences of control versus nicotine
pretreated cells, using unpaired, two-tailed t tests.
Measurements of noradrenaline and GABA in cultured cells
were done by enzyme immunoassays according to the manufac-
turer’s instructions (noradrenaline: 2-CAT ELISA, GABA: GABA
Elisa, Rocky Mountain Diagnostic, Inc., Colorado Springs, CO,
USA). Absorbance was read with an ELISA reader at 450 nm.
Quantification of the samples was achieved by comparing their
absorbance with a reference curve prepared with known standard
concentrations of noradrenaline and GABA. Data are expressed as
mean values and standard errors from triplicate samples per
treatment group. Statistical significance of data was assessed by
one-way analysis of variance (ANOVA), the Tukey-Kramer
multiple comparison test, and two-tailed, unpaired t test.
Assessment of cell proliferation by MTT assay
The colorimetric 3-(4, 5-dimethyle thiazol-2-yl)-2, 5-diphenyl
tetrazolium bromide (MTT) assay (Sigma) was performed as
previously described [31] to assess the concentration dependence
of inhibitory effects of GABA on cell proliferation. NSCLC cells
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data were then analyzed by nonlinear regression using GraphPad
Prism software.
Also, an MTT assay was used to determine the effect of acute or
chronic nicotine on NSCLC cells in the presence or absence of the
general b-adrenergic antagonist (synonym: beta-blocker) propran-
olol (Sigma). The dose of nicotine used in this study was within the
range of daily nicotine intake in heavy smokers [32].
Determination of DNA synthesis by [
3H]-thymidine
incorporation assay
Analysis of DNA synthesis by [
3H]-thymidine incorporation
assay was conducted as previously described [28]. Briefly, cells
were seeded into 96-well plates (5610
3 cells/well, triplicate wells/
treatment group) in complete RPMI-1640 and allowed to settle;
following 24-hour incubation in 37uC in an atmosphere of 5%
CO2 and 99% RH, complete medium was then replaced by fresh,
low-serum medium (0.1% FBS) for 24-hour starvation, at the end
of which medium was replaced by fresh, low-serum medium
containing [
3H]-thymidine (0.5 mCi/well) and treatment agents
(inhibitor: 1 mM propranolol, or stimulator: 1 mM epinephrine,
Sigma, or a combination of 1 mM propranolol for 10 minutes’
preincubation followed by 1 mM epinephrine) or vehicle in a final
volume of 200 ml/well. Following an additional incubation period
of 24 hours in the presence of the treatment agents in 5% CO2
and 99% RH at 37uC, cells were washed three times with PBS and
lysed, adding 30 ml/well of 0.1 N NaOH. The plate was incubated
at room temperature on a horizontal orbital microplate shaker.
Free [
3H]-thymidine was separated from incorporated [
3H]-
thymidine by vacuum filtration using a microplate harvester
(Micromate 196, Packard, Meriden, CT, USA) onto backed glass
fiber filters. The filters were flushed with isopropanol (200 ml/well)
to fix adsorbed DNA and transferred to scintillation vials
containing 3 ml counting cocktail (Bio-Safe-II, IL, USA). Radio-
activity bound to the filters was measured by liquid scintillation
spectrophotometry (Packard BioScience, Waltham, Massachusetts,
USA). GraphPad software was used to analyze data. Means and
standard errors were generated for count per minute. Significant
differences between groups were assessed by ANOVA and
unpaired Student t test.
Protein expression analysis of nAChRs and their effectors
by Western blotting
To assess the effects of one-time nicotine exposure versus
chronic exposure on the expression of nAChRs subunits (a7, a4),
glutamate decarboxylase (GAD65), and the mitogen-activated
protein kinases ERK1/2 or the cAMP response element binding
protein CREB, NSCLC cells were seeded into tissue culture dishes
(100 cm
2) containing their growth media. When the cells had
reached 60–65% confluence, they were rinsed once with 16PBS
and starved of serum for 24 hours. Following removal of the media
and replacement with fresh basal media, nicotine (1 mM) and cells
were incubated for 30 minutes in serum-free media with heat-
inactivated horse serum for 7 days. In another set of experiments,
cells were seeded into 100 cm
2 culture dishes containing their
growth media until they had reached 60–65% confluence, and
then cells were switched into basal media for 24-hour starvation.
Following starvation, fresh basal media was added containing the
treatments (1 mM nicotine, 30 minutes; 1 mM propranolol,
40 minutes; or a combination of propranolol for 10 minutes
followed by co-treatment with nicotine for 30 minutes). Following
treatments, cells were then washed once with cold 16 PBS
followed by cell lysate collection in which the protein concentra-
tion was estimated by BCA Protein Assay (Pierce, Rockford, IL,
USA). Western blotting procedure was conducted as previously
described [26]. Following blocking, membranes were then
incubated with primary antibodies overnight at 4uC. These
antibodies included total CREB (Upstate Biotechnology, Lake
Placid, NY, USA), p-CREB, p-ERK1/2 and ERK1/2 (Cell
Signaling, Danvers, MA, USA), anti-a4nAChR, a7nAChR,
GAD65 (Millipore, Billerica, MA, USA) and anti-beta-actin
(Sigma). After incubation with horseradish peroxidase-labeled
secondary antibody (anti-mouse or anti-rabbit, Cell Signaling) for
1 hour at room temperature, immunoreactive bands were
detected by chemiluminescent reaction (ECL, Amersham Biosci-
ences, Piscataway, NJ, USA) via autoradiography on Kodak Bio-
Max XAR film. Relative densities of the bands were determined
by image analysis using NIH SCION image analysis software.
Mean values and standard errors from five densitometric readings
per band were analyzed by one-way ANOVA and Tukey-Kramer
multiple comparisons test or by non-parametric ANOVA and
Mann-Whitney test as appropriate.
Results
NSCLC cells release the neurotransmitters noradrenaline
and GABA in response to nicotine, and these effects are
inhibited by a7o ra4 nAChR antagonists
Exposure of NCI-H322 cells to a single dose (1 mM) of nicotine
for 30 minutes caused a significant (P,0.001) increase in
noradrenaline production (Fig. 1). This response was significantly
(P,0.001) inhibited by the selective a7nAChR antagonist a-BTX
(200 nM; Fig. 1). At the same time, nicotine significantly (P,0.01)
reduced GABA production, an effect reversed (P,0.01) by the
selective a4b2nAChR antagonist NMDNI (Fig. 1).
Figure 1. Effect of acute nicotine exposure (Nic, 1 mM for
30 minutes) on the production of noradrenaline and GABA in
NCI-H322 cells. Production of noradrenaline was significantly
(P,0.001) increased (ELISA immunoassay), an effect inhibited by the
a7nAChR antagonist a-bungarotoxin (a-BTX, 200 nM for 30 minutes).
Production of GABA was significantly (P,0.001) reduced by nicotine, a
response blocked by the a4b2nAChR antagonist N-n-decylnicotinium
iodide (NDNI, 200 nM). Columns are mean values and standard errors of
triplicate samples per treatment group.
doi:10.1371/journal.pone.0029915.g001
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concentrations of nicotine established clear dose-response curves
(as indicated by goodness of fit R squared values between 0.9685
and 0.97320) for the stimulating effects of nicotine on noradren-
aline production (Fig. 2A) and the suppressing effect on GABA
release (Fig. 2B). The noradrenergic response was significantly
increased in cells pretreated for 7 days with nicotine, as evidenced
by a significantly lower EC50 in the nicotine pretreated cells (EC50
for unpretreated cells: 11.260.10 nM; EC50 for nicotine pretreat-
ed cells: 1.260.11 nM). These findings indicate that the
a7nAChR that regulates noradrenaline production was 9.2 times
more sensitive to nicotine in cells pretreated for 7 days with
nicotine than in unpretreated cells. In addition, the suppressing
effects of nicotine on GABA production were significantly
(P,0.0001) increased by chronic pre-exposure to nicotine
(Fig. 2B), with EC50 values of 11.260.83 nM and 1.460.81 nM,
respectively. These findings indicate that the a4b2nAChR was 7.9
times more desensitized by 7 days of nicotine exposure than by a
single nicotine exposure for 30 minutes.
Acute or chronic exposure to nicotine increases, and
GABA or propranolol inhibits cell proliferation
To assess the inhibitory effects of GABA on NCI-H322 cell
proliferation, dose-response curves were established, using MTT
assays. As exemplified in Fig. 3, the number of viable cells
decreased with increasing concentrations of GABA, yielding an
EC50 of 2.3 mM (Fig. 3). By contrast, MTT assays in NCI-H441
and NCI-H1299 cells showed that acute (30 minutes) as well as
chronic (7 days) exposure to nicotine (1 mM) significantly
(P,0.0001) increased the number of viable cells with chronic
exposure doubling this response (Fig. 4). These acute and chronic
responses of both cell lines to nicotine were significantly
(P,0.0001) inhibited by the broad-spectrum b-adrenergic antag-
onist propranolol (1 mM; Fig. 4). The difference between the group
treated with propranolol alone versus the group treated with
nicotine and propranolol in both cell lines were statistically
significant (P,0.001; Fig. 4).
Exogenously-added epinephrine induces DNA synthesis
in NSCLC cells
Determination of [
3H]-thymidine incorporation revealed a
significant (P,0.001) increase in DNA synthesis in NCI-H441
cells (2.9-fold) when epinephrine (1 mM) was added to the culture
medium and a 2-fold increase in NCI-H322 cells. This response
was significantly (P,0.001) inhibited in both cell lines by the
broad-spectrum b-adrenergic antagonist propranolol (1 mM;
Fig. 5).
Nicotine enhances the expression of nAChR subunits, p-
CREB and p-ERK while suppressing GAD65
Protein expression of a7nAChR in NCI-H322 cells increased
2.2 fold (P,0.001) after acute nicotine exposure and 2.7 fold after
chronic exposure, while expression of a4b2nAChR increased 1.8
(P,0.001) and 3.6 fold (P,0.001), respectively (Fig. 6A). Expres-
sion of the GABA-synthesizing enzyme GAD65 decreased to 0.7
and 0.3 fold, respectively, in cells treated with nicotine for
30 minutes or 7 days (Fig. 6A).
Protein analysis of the unphosphorylated and phosphorylated
forms of CREB and ERK revealed significant (P,0.001) increases
Figure 2. Dose-response curves of noradrenaline (A) and GABA
(B) production by NCI-H322 cells acutely and chronically
exposed to nicotine (1 mM). Data were generated by ELISA assays,
analyzed by nonlinear regression, and fitted to sigmoidal dose-response
curves. The resulting EC50 values were tested for statistically significant
differences by an unpaired t test. Chronic nicotine pretreatment for 7
days significantly (P,0.001) increased the noradrenergic response while
significantly (P,0.001) reducing the GABA response. Data points in the
graphs are mean values and standard errors of triplicate samples.
doi:10.1371/journal.pone.0029915.g002
Figure 3. Dose-dependence of GABA treatment on tumor cell
proliferation in NCI-H322 cells. Results from MTT assays were
conducted in vitro. Nonlinear regression analysis fitted for a sigmoidal
dose-response curve established an EC50 of 2.3 mM. Data points are
mean values and standard deviations of five samples per GABA
concentration.
doi:10.1371/journal.pone.0029915.g003
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nicotine, as opposed to chronically-exposed cells. The intensity of
this response was particularly noteworthy for p-ERK, which
showed a 6.6-fold increase in the nicotine pretreated cells
compared with only a 2.2-fold increase in the unpretreated cells
(Fig. 6B). On the other hand, NCI-H441 cells treated with1 mM
nicotine for 30 minutes showed a 2.75-fold increase in p-CREB
(P,0.001) and a 2.9-fold increase in p-ERK1/2 (P,0.001)
(Fig. 7A), while Western blot analysis of NCI-H1299 cells treated
with1 mM nicotine for 30 minutes revealed a 3.8-fold increase in
p-CREB (P,0.001) and a 4.1-fold increase in p-ERK1/2
(P,0.001) (Fig. 7B). Both responses were significantly reduced
by 1 mM propranolol (P,0.0001) in both cell lines, as illustrated in
Fig. 7.
These findings are in accord with the observed nicotine-induced
increase in the stimulatory noradrenergic response and decrease in
inhibitory GABA response after chronic nicotine exposure,
resulting in hyperactivity of CREB and ERK.
Discussion
Our data provide evidence, for the first time, that NSCLC cells
produce their own stimulatory and inhibitory neurotransmitters
and that these activities are regulated by nAChRs. The production
of catecholamines by NSCLC cells observed in the current
experiments is in accord with published observations that a
significant number of NSCLC tumors and cell lines express the
enzyme dopa-decarboxylase which mediates the conversion of L-
Dopa to dopamine from which noradrenaline is formed [33]. The
in vivo relevance of the current in vitro data is additionally
supported by a recent report that nicotine-induced induction of
NSCLC xenograft growth is reversed by the pharmacological
Figure 4. Inhibitory effects of propranolol in NCI-H441 and NCI-H1299 cells. Cells exposed to the broad spectrum antagonist of the b-
adrenergic receptor propranolol (1 mM) prior to acute and chronic exposure to nicotine (1 mM) showed a significant reduction in viable cell numbers
as assessed by the MTT assay. Cells were preincubated for 10 minutes with the inhibitor and then exposed for 24 hours to nicotine in the presence of
inhibitor. The stimulatory response to nicotine was significantly reduced (P,0.0001). Also, the difference between the group treated with propranolol
alone versus the group treated with nicotine and propranolol in both cell lines were statistically significant (P,0.001). Bars represent mean values and
standard errors of three independent experiments, each with five replicate samples.
doi:10.1371/journal.pone.0029915.g004
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of the a7nAChR for the production of noradrenaline and of the
a4b2nAChR for the production of GABA by NSCLC cells are
analogous to the function of these receptors in the brain where
noradrenaline has excitatory effects, whereas GABA acts as the
main inhibitory neurotransmitter [13,14]. Our data show that the
a7nAChR-induced release of noradrenaline significantly stimulat-
ed NSCLC proliferation associated with the induction of p-ERK
and p-CREB while the observed reversal of these effects by
propranolol identify these and potentially other signaling proteins
as the downstream effectors of b-ARs. The resulting cooperation
of a7nAChR and b-ARs represents an attractive novel target for
the development of more effective intervention strategies for
NSCLC.
Nicotine-induced stimulation of DNA synthesis and inhibition
of apoptosis were first reported in neuroendocrine lung cancer
cells [35,36]. Since then, numerous publications have described
intracellular signaling in response to nAChR activation by nicotine
or NNK and interpreted these effects as direct responses
downstream of nAChRs [reviewed in 6]. However, a major
function of nAChR-induced cation influx in the central nervous
system is the regulation of excitatory and inhibitory neurotrans-
mitters [6], suggesting that non-neuronal cells may respond in a
similar fashion. This hypothesis is supported by our current data
and is in accord with recent findings that hamsters with NNK-
induced ACs have increased serum levels of noradrenaline and
adrenaline accompanied by elevated cAMP in blood cells and
tumor tissue [37]. Strong cancer-stimulating effects of noradren-
aline and adrenaline, or stress that induces the release of these
neurotransmitters from the adrenal medulla and sympathetic
nerves, have also been demonstrated in cancer of the colon [22],
prostate [24], mammary gland [38], and ovary [25,39].
Our data show that chronic exposure of NSCLC cells to
nicotine modulated the expression and function of a7nAChR and
a4b2nAChR in a manner that enhanced the levels of cancer-
stimulating noradrenaline while suppressing cancer-inhibiting
GABA. These findings are in accord with the recently reported
tumor suppressor function of GABA in NSCLC [40].
The observed upregulation of a7nAChR protein in conjunction
with increased stress neurotransmitters, cAMP, and induced p-
Figure 5. Epinephrine increased DNA synthesis, an effect
blocked by propranolol. Single doses of epinephrine (1 mM) yielded
a 2-fold increase (P,0.0.001) in DNA synthesis in NCI-H322 cells and a
2.8-fold increase (P,0.0001) in NCI-H441 cells ([3H]-thymidine incorpo-
ration assay). This effect was blocked and the DNA synthesis was
inhibited by the broad-spectrum b-adrenergic receptor propranolol
(1 mM). Data are mean values and standard errors of triplicate samples
per treatment group and are expressed as normalized values relative to
the control (100%) showing that variation among group medians was
significantly (P,0.0001) greater than expected by chance using a non-
parametric ANOVA.
doi:10.1371/journal.pone.0029915.g005
Figure 6. Protein expression of a7nAChR (a7), a4b2nAChR (a4),
the GABA synthesizing enzyme GAD65 (A), p-CREB, CREB, p-
ERK1/2, and ERK1/2 (B) in response to acute or chronic nicotine
(1 mM) exposure in NCI-H322 cells. These Western blots illustrate
that both nAChRs showed a significant (P,0.001) increase in protein
expression after 30 minutes of nicotine exposure, an effect enhanced
further by exposure to nicotine for 7 days. By contrast, the expression of
GAD65 protein was significantly (P,0.001) reduced. Expression of p-
ERK and p-CREB was significantly (P,0.001) increased in acutely-
exposed cells. These responses were further increased (P,0.01 for p-
CREB, P,0.001 for p-ERK1/2) by chronic pre-exposure to nicotine. Data
in the graphs are mean values and standard errors of five densitometric
readings per band calculated as ration of protein of interest over actin
(A) or as ratio of phosphorylated proteins over the respective
unphosphorylated proteins (B) and expressed as fold increase over
untreated controls.
doi:10.1371/journal.pone.0029915.g006
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nicotine exposure rendered this receptor hyperactive. By contrast,
upregulation in a4nAChR protein accompanied by suppression of
GAD65 and GABA suggests that nicotine causes long-term
desensitization of this receptor, resulting in a reactive upregulation
of receptor protein. In support of this interpretation, our in vitro
Figure 7. Western immunoblot analyses in NCI-H441 (A) and NCI-H1299 cells (B). Nicotine (1 mM for 30 minutes) increased the expression
of p-CREB (NCI-H441:2.75 fold, P,0.001; NCI-H1299: 3.8-fold, P,0.001) and p-ERK1/2 (NCI-H441: 2.9 fold, P,0.001; NCI-H1299: 4.1 fold, P,0.001).
Propranolol inhibited induction of these phosphorylated proteins (P,0.001) in both cell lines. CREB and ERK1/2 were used as housekeeping proteins
to ensure equal protein loading. Columns in the graph represent mean values and standard errors of five densitometric readings per band, expressed
as a ratio of p-CREB over CREB or p-ERK over ERK1/2.
doi:10.1371/journal.pone.0029915.g007
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noradrenergic response and down-regulated GABA response in
AC cells pre-exposed for 7 days to nicotine. The observed increase
in noradrenergic response was significantly greater than the
nicotine-induced increase in a7nAChR protein, indicating that
a7nAChR was significantly sensitized to the agonist. Moreover,
the significant decrease in GABA response observed in cells
chronically exposed to nicotine supports the interpretation of a
desensitized a4b2nAChR that regulates GABA production in
these cells. Our findings are in accord with the ‘‘paradoxical’’
(without long-term desensitization) upregulation of a7nACHR as
opposed to the desensitization-induced upregulation of
a4b2nAChR in response to chronic nicotine reported in the brain
[11,13] and demonstrate strong analogy to modulations of these
receptors in the brain associated with nicotine addiction. In turn,
the resulting hyperactivity of NSCLC-stimulating beta-adrenergic
signaling suggests an important role of this cascade in the
development and progression of this cancer in smokers. A recent
electrophysiological study with immortalized human bronchial
epithelial cells has shown that in vitro exposure to 1 mM nicotine
for 48 hours significantly increased nicotine-induced currents [41],
while investigations with immortalized human small airway
epithelial cells have shown that exposure for 7 days to NNK
caused a significant increase in the noradrenergic response of these
cells to a nicotinic agonist [42]. Studies by PCR analyses have
reported down-regulated gene expression of the a4nACHR
subunit in the majority of investigated tissue samples from human
ACs [43]. Although these studies were not accompanied by
analyses of receptor protein expression that would detect
posttranscriptional protein upregulation of the receptor in
response to chronic nicotine [16,17], they provide additional
support for a reduced function of a4b2nAChR in human AC.
NNK is an agonist for nAChRs [7] as well as b-ARs [28], and in
vitro studies with NSCLC cells and small airway epithelial cells
have shown that beta-adrenergic receptor activation by a synthetic
agonist or NNK activated the adenylyl cyclase/cAMP/PKA/
CREB cascade while at the same time trans-activating EGFR and
its downstream effectors in a PKA-dependent manner [27–29,44].
Our current findings suggest that some of these signaling responses
to NNK were triggered by the a7nAChR-activated release of
noradrenaline. In addition, our findings suggest that nicotine-
induced promotion of NSCLC growth reported in xenograft
models [45] was at least in part caused by the nAChR-mediated
release of noradrenaline and adrenaline into the systemic
circulation. At the same time, production of endogenous GABA,
which serves as the physiological inhibitor of this signaling
cascade, was suppressed due to nicotine-induced, long-term de-
sensitization of its regulatory a4b2nAChR. The simultaneous
downregulation of GAD 65, as shown in our study, is in accord
with observations that stress characterized by acetylcholine-
induced activation of nAChR-mediated release of noradrenaline,
adrenaline, and cortisol reduces GAD and GABA, resulting in an
impaired GABA system [46]. While the mechanisms underlying
these effects are poorly understood, the nicotine-induced increase
in these stress neurotransmitters, accompanied by downregulation
of GAD 65 and GABA levels in our study and their reversal by
propranolol treatment is extremely encouraging, with potential for
marker-guided prevention and adjuvant therapy of AC. This
conclusion is supported by observations that propranolol prevent-
ed the development of NNK-induced NSCLC in hamsters that
overexpressed the a7nAChR, p-CREB and p-ERK [47] while
showing suppressed GAD expression [37], whereas epinephrine
had strong tumor promoting effects [47]. The reversal of nicotine-
induced effects by propranolol treatment in the current study is
also in accord with reports that the posttranscriptional upregula-
tion of nAChRs by nicotine is PKA dependent [48], as PKA is a
substrate of cAMP formed downstream of b-ARs.
In summary, the cooperative regulation of NSCLC cells by
nAChRs and b-ARs and the strong inhibiting effects of
propranolol at several levels of these pathways identify agents
that interfere with this regulatory cascade as promising new tools
for marker-guided prevention and adjuvant therapy of a subset of
NSCLCs.
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